( June 4, 2026, 06:25 GMT | Official Statement) -- MLex Summary: Boryung won conditional approval from the Korea Fair Trade Commission for its acquisition of worldwide commercial rights to Sanofi's Taxotere, an original docetaxel cancer drug used primarily to treat breast cancer, after the regulator found the deal would substantially restrict competition in the domestic market. Boryung, which already sells the generic docetaxel product Ditaxel, would have controlled up to 78.5 percent of South Korea's docetaxel cancer-drug market following the transaction, far ahead of six remaining rivals with single-digit shares. The regulator ordered Boryung to divest the Ditaxel business to a third party within six months and barred it from halting Ditaxel production or supply, or steering customers to Taxotere, before the sale is completed. It also required Boryung to supply finished Ditaxel products and provide technical support for a period after the sale if requested by the buyer.Statement is attached (in Korean)....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.